Physician profile
David R Slay
NPI 1801898630
$1,467.28
in general payments reported to CMS, 2019-2025
28 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $84.99 · 2021: $473 · 2022: $227 · 2023: $149 · 2024: $153 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.83 | 2021-2024 | Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $112.69 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $110.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.74 | 2019-2021 | |
| Lilly USA, LLC | $68.68 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $61.70 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.98 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $52.71 | 2022-2024 | Trelegy Ellipta |
| Pfizer INC. | $43.72 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.81 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.84 | 2023-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $31.79 | 2019-2021 | |
| Horizon Therapeutics Plc | $30.77 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $29.15 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.89 | 2021 | |
| Boston Scientific Corporation | $26.53 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.34 | 2025 | Givlaari |
| Genentech USA, INC. | $17.66 | 2020 | |
| Allergan, INC. | $17.30 | 2020 | |
| Lundbeck LLC | $16.17 | 2025 | Rexulti |
| Dermira, INC. | $16.14 | 2019 | |
| Novo Nordisk INC | $14.75 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.71 | 2021 | |
| Shire North American Group INC | $13.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.36 | 2021 | |
| Amgen INC. | $12.23 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Slay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.